AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Fate Therapeutics Inc (NASDAQ:FATE)
1.565 USD
+0.225 16.791%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.34 |
|---|---|
| Change | +0.225 16.791% |
| 52 W H/L (in USD) | 8.830/1.630 |
| EBITDA (in USD) | -181.175M |
| PE Ratio | -- |
| Volume | 2363772 |
| Diluted Eps TTM | -1.93 |
| Total Assets (in USD) | 506.217M |
|---|---|
| Total Liabilities (in USD) | 137.8M |
| Revenue TTM (in USD) | 6.478M |
| Cash (in USD) | 41.87M |
| Market Cap (in USD) | 402.965 M |
| Revenue Per Share TTM | 0.065 |
| Gross Profit TTM (in USD) | -224.154M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
12278 Scripps Summit Drive, San Diego, CA, United States, 92131
858 875 1800
Employees: 181
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. J. Scott Wolchko | Founder, CEO, Pres & Director | 1970 |
| 2. | Mr. Edward J. Dulac III | Chief Financial Officer | 1976 |
| 3. | Dr. Mark Plavsic D.V.M., Ph.D. | Chief Technical Officer | 1961 |
| 4. | Ms. Cindy R. Tahl | Gen. Counsel & Corp. Sec. | 1973 |
| 5. | Dr. Bahram Valamehr Ph.D. | Chief R&D Officer | 1977 |
| 6. | Dr. Yu-Waye Chu M.D. | Chief Medical Officer | NA |
| 7. | Mr. Jim Beitel M.B.A. | Sr. VP of Corp. Devel. | NA |
| 8. | Dr. Sarah Cooley | Sr. VP of Clinical Translation | NA |
| 9. | Dr. Jerome Bressi Ph.D. | Sr. VP of Regulatory Affairs & Quality | NA |
| 10. | Mr. Brian T. Powl M.B.A., M.S. | Chief Commercial Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.930 2.657% | 74.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.352 0.482% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+4.320 0.973% | 443.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.300 2.546% | 485.54 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -281.721M | -212.151M | -173.387M | -98.149M | -66.598M |
| Minority Interest | - | - | - | - | - |
| Net Income | -255.056M | -206.301M | -170.3M | -97.708M | -66.598M |
| Selling General Administrative | 84.232M | 57.321M | 33.896M | 23.637M | 15.808M |
| Gross Profit | 96.3M | 55.846M | 31.434M | 10.68M | 4.74M |
| Reconciled Depreciation | 13.758M | 5.85M | 3.087M | 2.193M | 1.204M |
| Ebit | -322.144M | -216.994M | -128.085M | -100.727M | -66.106M |
| Ebitda | -308.386M | -215.685M | -125.685M | -96.397M | -64.902M |
| Depreciation And Amortization | 13.758M | 1.309M | 2.4M | 4.33M | 1.204M |
| Operating Income | -308.386M | -216.994M | -128.085M | -100.727M | -67.092M |
| Other Operating Expenses | 404.686M | 272.84M | 159.519M | 111.407M | 71.832M |
| Interest Expense | 5.842M | 4.541M | 2.4M | 1.752M | 1.696M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 5.842M | 1.309M | 2.4M | 4.33M | 2.19M |
| Net Interest Income | 5.842M | 1.309M | 2.4M | 2.578M | 0.494M |
| Income Tax Expense | -26.665M | -5.85M | -3.087M | -0.441M | 2.19M |
| Total Revenue | 96.3M | 55.846M | 31.434M | 10.68M | 4.74M |
| Total Operating Expenses | 404.686M | 272.84M | 159.519M | 111.407M | 71.832M |
| Cost Of Revenue | - | - | - | 87.77M | 56.024M |
| Total Other Income Expense Net | 26.665M | 4.843M | -45.302M | 2.578M | 0.494M |
| Net Income From Continuing Ops | -281.721M | -212.151M | -173.387M | -98.149M | -66.598M |
| Net Income Applicable To Common Shares | -281.721M | -212.151M | -173.387M | -98.149M | -66.598M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 506.217M | 705.561M | 921.455M | 622.457M | 302.274M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 13.639M | 27.367M | 8.826M | 5.892M | 4.324M |
| Total Liab | 137.8M | 221.622M | 242.617M | 238.012M | 57.518M |
| Total Stockholder Equity | 368.417M | 483.939M | 678.838M | 384.445M | 244.756M |
| Other Current Liab | 27.514M | 57.932M | 45.612M | 54.782M | 17.505M |
| Common Stock | 0.099M | 0.097M | 0.096M | 0.088M | 0.076M |
| Capital Stock | 0.102M | 0.1M | 0.099M | 0.091M | 0.079M |
| Retained Earnings | -1211.732M | -1050.804M | -769.083M | -556.932M | -383.545M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 22.456M | 25.13M | 95.826M | 1.574M |
| Cash | 41.87M | 61.333M | 133.583M | 167.347M | 99.814M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 39.094M | 114.051M | 81.284M | 85.564M | 27.806M |
| Current Deferred Revenue | 0.685M | 42.226M | 21.483M | 21.144M | 2.787M |
| Net Debt | 61.666M | 48.005M | -18.765M | -70.049M | -72.887M |
| Short Term Debt | 6.176M | 5.628M | 5.577M | 3.355M | 1.692M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 103.536M | 109.338M | 114.818M | 97.298M | 26.927M |
| Other Stockholder Equity | 1580.032M | 1536.497M | 1448.584M | 941.216M | 628.2M |
| Property Plant Equipment | - | 176.089M | 162.249M | 32.308M | 11.419M |
| Total Current Assets | 331.54M | 502.074M | 633.412M | 494.323M | 227.089M |
| Long Term Investments | 0.98M | 4.942M | 100.664M | 0M | 39.44M |
| Short Term Investments | 273.305M | 374.894M | 482.327M | 315.569M | 121.613M |
| Net Receivables | 2.726M | 38.48M | 8.676M | 5.515M | 1.338M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 4.719M | 8.265M | 8.612M | 6.283M | 5.822M |
| Accumulated Other Comprehensive Income | 0.015M | -1.854M | -0.762M | 0.07M | 0.022M |
| Non Currrent Assets Other | 0.009M | 132.476M | 116.659M | 61.05M | 12.993M |
| Non Current Assets Total | 174.677M | 203.487M | 288.043M | 128.134M | 75.185M |
| Capital Lease Obligations | 103.536M | 109.338M | 114.818M | 97.298M | 26.927M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 166.751M | -273.319M | -156.144M | -150.058M | 1.84M |
| Total Cashflows From Investing Activities | 166.751M | -324.023M | -161.076M | -157.453M | -0.463M |
| Total Cash From Financing Activities | 9.207M | 453.129M | 282.838M | 149.928M | 140.78M |
| Net Income | -281.721M | -212.151M | -173.387M | -98.149M | -66.598M |
| Change In Cash | -72.25M | -33.764M | 82.533M | -90.7M | 101.667M |
| Begin Period Cash Flow | 148.81M | 182.574M | 100.041M | 190.741M | 89.074M |
| End Period Cash Flow | 76.56M | 148.81M | 182.574M | 100.041M | 190.741M |
| Total Cash From Operating Activities | -248.208M | -162.87M | -39.229M | -83.175M | -38.65M |
| Depreciation | 13.758M | 5.85M | 3.087M | 2.193M | 1.204M |
| Other Cashflows From Investing Activities | - | - | - | -150.058M | 1.84M |
| Dividends Paid | - | - | - | -2.522M | - |
| Change To Inventory | - | -5.907M | 1.554M | -4.277M | -4.254M |
| Sale Purchase Of Stock | - | 432.449M | 248.414M | 2.522M | 2.693M |
| Other Cashflows From Financing Activities | 166.751M | 41.394M | 10.145M | 2.522M | 3.51M |
| Capital Expenditures | 35.566M | 50.704M | 4.932M | 7.395M | 2.303M |
| Change In Working Capital | -34.71M | 2.098M | -12.773M | 3.64M | 1.744M |
| Other Non Cash Items | -24.268M | -18.098M | 111.415M | -7.791M | 19.042M |
| Free Cash Flow | -283.774M | -213.574M | -44.161M | -90.57M | -40.953M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | SPDR® S&P Biotech ETF | 1 year ago | 5665026 |
| 2. | BB Biotech AG Ord | 1 year ago | 4839779 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 2962285 |
| 4. | Vanguard Strategic Equity Inv | 1 year ago | 2097908 |
| 5. | iShares Russell 2000 ETF | 1 year ago | 1982253 |
| 6. | Vanguard Explorer Inv | 1 year ago | 1344742 |
| 7. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 1249141 |
| 8. | Fidelity Small Cap Index | 1 year ago | 869103 |
| 9. | BlackRock Advantage Small Cap Core Instl | 1 year ago | 831258 |
| 10. | iShares Russell 2000 Value ETF | 1 year ago | 782157 |
| 11. | Vanguard Strategic Small-Cap Equity Inv | 1 year ago | 758542 |
| 12. | Federated Hermes MDT Small Cap Core IS | 1 year ago | 666781 |
| 13. | Federated Hermes MDT SCC Institutional | 1 year ago | 666781 |
| 14. | Direxion Daily S&P Biotech Bull 3X ETF | 1 year ago | 570082 |
| 15. | JPMorgan Small Cap Value I | 1 year ago | 564337 |
| 16. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 526611 |
| 17. | Invesco Dorsey Wright SmallCap Momt ETF | 1 year ago | 497540 |
| 18. | Fidelity Extended Market Index | 1 year ago | 482240 |
| 19. | JPM Thematics Genetic Thrps C2 Acc USD | 1 year ago | 447851 |
| 20. | Schwab US Small-Cap ETF™ | 1 year ago | 391154 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Redmile Group, LLC | 1 year ago | 13124427 |
| 2. | BlackRock Inc | 1 year ago | 11212816 |
| 3. | Vanguard Group Inc | 1 year ago | 9293363 |
| 4. | Bellevue Group AG | 1 year ago | 4851579 |
| 5. | D. E. Shaw & Co LP | 1 year ago | 4711664 |
| 6. | Johnson & Johnson | 1 year ago | 3379064 |
| 7. | Assenagon Asset Management SA | 1 year ago | 2548304 |
| 8. | Jacobs Levy Equity Management, Inc. | 1 year ago | 2389123 |
| 9. | Acadian Asset Management LLC | 1 year ago | 2281171 |
| 10. | Monaco Asset Management | 1 year ago | 2183228 |
| 11. | JPMorgan Chase & Co | 1 year ago | 2072506 |
| 12. | Casdin Capital, LLC | 1 year ago | 2050000 |
| 13. | Citadel Advisors Llc | 1 year ago | 2019632 |
| 14. | Two Sigma Advisers, LLC | 1 year ago | 1876900 |
| 15. | Geode Capital Management, LLC | 1 year ago | 1863485 |
| 16. | State Street Corporation | 1 year ago | 1861919 |
| 17. | Federated Hermes Inc | 1 year ago | 1849872 |
| 18. | Adage Capital Partners Gp LLC | 1 year ago | 1700000 |
| 19. | Two Sigma Investments LLC | 1 year ago | 1550659 |
| 20. | Morgan Stanley - Brokerage Accounts | 1 year ago | 1321356 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...